Loading
A phase 1/2 trial of an investigational treatment in non-Hodgkin lymphoma, run by Otsuka Medical Devices Co., Ltd. Japan, now recruiting.
A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma is a phase 1/2 interventional study registered as NCT07075328 by Otsuka Medical Devices Co., Ltd. Japan, with 49 participants planned, started 2024-04-01 and due to reach its primary completion in 2028-02-28.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Otsuka Pharmaceutical and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Otsuka Pharmaceutical and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.